PATENT CLAIM ANALYSIS

Application Number: 16101861
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "158100"]

Abstract:
Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.

Claim (Index 6):
The antibody or antigen binding fragment of  claim 1  wherein the antibody or antigen binding fragment comprises:\n (a) a heavy chain (HC) having a variable domain comprising a heavy chain complementarity determining region (HC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:1, an HC-CDR 2 having the amino acid sequence shown in SEQ ID NO:2, and an HC-CDR 3 having the amino acid sequence shown in SEQ ID NO:3; or \n (b) a heavy chain (HC) having a variable domain comprising an HC-CDR 1 having the amino acid sequence shown in SEQ ID NO:7, an HC-CDR 2 having the amino acid sequence shown in SEQ ID NO:8, and an HC-CDR 3 having the amino acid sequence shown in SEQ ID NO:9, \n and \n (a) a light chain (LC) having a variable domain comprising a light chain complementarity determining region (LC-CDR) 1 having the amino acid sequence shown in SEQ ID NO:4, an LC-CDR 2 having the amino acid sequence shown in SEQ ID NO:5, and an LC-CDR 3 having the amino acid sequence shown in SEQ ID NO:6; or \n (b) a light chain having a variable domain comprising an LC comprising an LC-CDR 1 having the amino acid sequence shown in SEQ ID NO:10, an LC-CDR 2 having the amino acid sequence shown in SEQ ID NO:11, and an LC-CDR 3 having the amino acid sequence shown in SEQ ID NO:12, \n wherein optionally the HC and LC variable domains independently comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof with the proviso that no CDR in the HC and LC variable domains has more than three amino acid substitutions, additions, deletions, or combinations thereof, and \n wherein the antibody or antigen binding fragment binds the apple 2 domain of coagulation factor XI (FXI) and inhibits activation of FXI.

Metadata:
- Claim Count in Document: 122.0
- Percentile: 96.0
- Lexical Diversity: 1.09091
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15409607', '15619620', '16335133', '15906773', '15934526']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7514638909270145
- 35 USC 102 Novelty (BERT): 0.7393939774634852
- Combined Prediction Score: 0.7502568995806616
- Mean Citation Score: 558.16293
- Max Citation Score: 887.4425699999997
- Similarity Product: 805.660106388781

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test